Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1123739 | 0.80 | ALDH1A1 (0.58) | PIK3R1PIK3CACTSKALDH1A1HPGD | |
| SCHEMBL1123953 | 0.80 | ALDH1A1 (0.58) | PIK3R1PIK3CACTSKALDH1A1HPGD | |
| SCHEMBL13650791 | 0.76 | CTSK (0.61) | CTSKKDM4EGAA | |
| SCHEMBL17822441 | 0.76 | HRH4 (0.59) | HRH4 | |
| SCHEMBL11285357 | 0.76 | HTR2C (0.74) | HTR2CHRH4NPSR1PIK3R1PIK3CA | |
| SCHEMBL1310780 | 0.76 | MAPT (0.60) | HTR2CHRH4NPSR1PIK3R1PIK3CA | |
| SCHEMBL10844743 | 0.75 | HRH4 (0.76) | HRH4NPSR1PIK3CAKMT2A | |
| SCHEMBL3177803 | 0.75 | HRH4 (0.76) | HRH4NPSR1PIK3CAKMT2A | |
| SCHEMBL11563163 | 0.75 | HTR1A (0.58) | HTR2C | |
| SCHEMBL11743139 | 0.75 | KDM4E (0.82) | HRH4PIK3R1PIK3CAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152519-A1 | PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-06-23 | — | — | US | claimed |
| EP-2284160-A1 | PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-02-16 | — | — | EP | claimed |
| US-8563715-B2 | Pyrimidine derivative having cell protecting effect and uses thereof | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8563715-B2 | Pyrimidine derivative having cell protecting effect and uses thereof | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8563715-B2 | Pyrimidine derivative having cell protecting effect and uses thereof | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2013-10-22 | — | — | US | disclosed |
| EP-2284160-B1 | PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF | ZENYAKU KOGYO KK (JP) | 2013-05-15 | — | — | EP | disclosed |
| US-20110152519-A1 | PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110152519-A1 | PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110152519-A1 | PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-06-23 | — | — | US | disclosed |
| EP-2284160-A1 | PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009123221-A1 | PYRIMIDINE DERIVATIVE HAVING CELL-PROTECTING ACTIVITY AND USE THEREOF | 全薬工業株式会社 (JP) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152519-A1 | PYRIMIDINE DERIVATIVE HAVING CELL PROTECTING EFFECT AND USES THEREOF | CASP3, DPYD, CASP1 | HTR2C 4352/4885HRH4 3298/4885NPSR1 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.